Inogen Company Profile (NASDAQ:INGN)

About Inogen (NASDAQ:INGN)

Inogen logoInogen, Inc. is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company's Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device. Its three portable product offerings, the Inogen One G4, Inogen One G3 and Inogen One G2, at approximately 2.8, 4.8 and 7.0 pounds with a single battery, respectively. Its Inogen One G4, Inogen One G3 and Inogen One G2 are sub-3, sub-5 and sub-10 pound portable oxygen concentrators, respectively. All of its Inogen One systems are equipped with Intelligent Delivery Technology. The Inogen At Home stationary oxygen concentrator allows it to access the non-ambulatory oxygen patient market and serves as a backup to its Inogen One system for ambulatory patients on its rental service.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:INGN
  • CUSIP: N/A
  • Web: www.inogen.com
Capitalization:
  • Market Cap: $1.96 billion
  • Outstanding Shares: 20,582,000
Average Prices:
  • 50 Day Moving Avg: $93.50
  • 200 Day Moving Avg: $79.08
  • 52 Week Range: $50.01 - $97.71
P/E:
  • Trailing P/E Ratio: 85.17
  • Foreward P/E Ratio: 76.18
  • P/E Growth: 2.96
Sales & Book Value:
  • Annual Revenue: $212.34 million
  • Price / Sales: 9.23
  • Book Value: $9.38 per share
  • Price / Book: 10.15
Profitability:
  • EBIDTA: $35.35 million
  • Net Margins: 9.32%
  • Return on Equity: 11.67%
  • Return on Assets: 9.66%
Debt:
  • Current Ratio: 6.98%
  • Quick Ratio: 6.43%
Misc:
  • Average Volume: 183,016 shs.
  • Beta: 1.04
  • Short Ratio: 4.85
 
Frequently Asked Questions for Inogen (NASDAQ:INGN)

What is Inogen's stock symbol?

Inogen trades on the NASDAQ under the ticker symbol "INGN."

How were Inogen's earnings last quarter?

Inogen, Inc (NASDAQ:INGN) posted its earnings results on Tuesday, May, 9th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.15. The company earned $52.50 million during the quarter, compared to analysts' expectations of $49.06 million. Inogen had a net margin of 9.32% and a return on equity of 11.67%. Inogen's quarterly revenue was up 22.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.12 EPS. View Inogen's Earnings History.

Where is Inogen's stock going? Where will Inogen's stock price be in 2017?

4 brokers have issued 1-year price targets for Inogen's shares. Their forecasts range from $75.00 to $108.00. On average, they expect Inogen's share price to reach $91.00 in the next year. View Analyst Ratings for Inogen.

What are analysts saying about Inogen stock?

Here are some recent quotes from research analysts about Inogen stock:

  • 1. According to Zacks Investment Research, "Over the last three months, Inogen outperformed the broader industry in terms of price. However, rental revenue headwinds are a concern, thanks to private insurance rate reductions, higher provisions for rental revenue adjustments and lower net patient additions. Inogen reported a solid first quarter of 2017, beating the Zacks Consensus Estimate on both the counts. Inogen generates a significant portion of its revenues from the International market. Volatility in foreign exchange rate is expected to mar the company’s top line in the coming quarters. Furthermore, the stock looks a bit overvalued at the moment when compared to the market at large. However, Inogen has provided a positive guidance for full-year 2017. The company’s unique direct-to-customer business model, an innovative product line and growing patient base are key catalysts in our view." (7/11/2017)
  • 2. Needham & Company LLC analysts commented, "INGN beat consensus revenue, EBITDA, and EPS in 1Q17. Management maintained its 2017 revenue and EBITDA guidance and raised its 2017 net income guidance. The revenue upside was driven by 49% growth in B2B more than offsetting 0% growth in DTC. We think that the strong 84% growth in domestic B2B provides further evidence that home medical equipment companies (HMEs) are increasingly adopting portable oxygen concentrators." (5/10/2017)
  • 3. Stifel Nicolaus analysts commented, "Inogen (INGN) reported 4Q16 after the close on February 28, 2017 with results better than our expectations. Revenue, Adjusted-EBITDA, and Net Income all exceeded our expectations. Management slightly raised its recently established 2017 guidance. In our view, INGN has a great longer-term story that should continue to evolve and grow as disruption occurs in the high cost delivery model of oxygen to those that need it. Maintain Hold and adjust target to $65 based on a range of valuation multiples." (3/1/2017)

Who are some of Inogen's key competitors?

Who are Inogen's key executives?

Inogen's management team includes the folowing people:

  • Heath Lukatch Ph.D., Independent Chairman of the Board
  • Scott Wilkinson, President, Chief Executive Officer, Director
  • Alison Bauerlein, Executive Vice President - Finance and Chief Financial Officer, Corporate Secretary and Corporate Treasurer
  • Byron Myers, Executive Vice President of Sales and Marketing
  • Matthew Scribner, Executive Vice President - Operations
  • Brenton Taylor, Executive Vice President - Engineering
  • Benjamin M. Anderson-Ray, Independent Director
  • Scott A. Beardsley, Independent Director
  • R. Scott Greer, Independent Director
  • Raymond O. Huggenberger, Independent Director

Who owns Inogen stock?

Inogen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (1.56%), Rockefeller Financial Services Inc. (1.51%), Bank of Montreal Can (0.25%), Mitsubishi UFJ Asset Management UK Ltd. (0.10%), Thomson Horstmann & Bryant Inc. (0.07%) and Curbstone Financial Management Corp (0.06%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Institutional Ownership Trends for Inogen.

Who sold Inogen stock? Who is selling Inogen stock?

Inogen's stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Bank of Montreal Can, Thomson Horstmann & Bryant Inc., Curbstone Financial Management Corp and Capstone Asset Management Co.. Company insiders that have sold Inogen stock in the last year include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Insider Buying and Selling for Inogen.

Who bought Inogen stock? Who is buying Inogen stock?

Inogen's stock was purchased by a variety of institutional investors in the last quarter, including Mitsubishi UFJ Asset Management UK Ltd., Rockefeller Financial Services Inc., Aperio Group LLC, Eqis Capital Management Inc. and State of Alaska Department of Revenue. View Insider Buying and Selling for Inogen.

How do I buy Inogen stock?

Shares of Inogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Inogen's stock price today?

One share of Inogen stock can currently be purchased for approximately $95.22.


MarketBeat Community Rating for Inogen (NASDAQ INGN)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  146 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  208
MarketBeat's community ratings are surveys of what our community members think about Inogen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Inogen (NASDAQ:INGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 1 Buy Rating, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $91.00 (4.43% downside)

Analysts' Ratings History for Inogen (NASDAQ:INGN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/26/2017J P Morgan Chase & CoBoost Price TargetOverweight$102.00LowView Rating Details
6/9/2017Needham & Company LLCBoost Price TargetStrong-Buy$96.00 -> $108.00LowView Rating Details
5/10/2017Stifel NicolausBoost Price TargetHold -> Hold$65.00 -> $75.00HighView Rating Details
4/18/2017SidotiInitiated CoverageNeutral -> Neutral$79.00MediumView Rating Details
6/8/2016Leerink SwannReiterated RatingOutperform$60.00N/AView Rating Details
3/24/2016Piper Jaffray CompaniesInitiated CoverageNeutral$46.00N/AView Rating Details
(Data available from 7/23/2015 forward)

Earnings

Earnings History for Inogen (NASDAQ:INGN)
Earnings by Quarter for Inogen (NASDAQ:INGN)
Earnings History by Quarter for Inogen (NASDAQ INGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017$0.12$0.27$49.06 million$52.50 millionViewListenView Earnings Details
2/28/2017Q416$0.10$0.25$46.19 million$50.85 millionViewListenView Earnings Details
11/3/2016Q316$0.13$0.16$47.89 million$54.42 millionViewN/AView Earnings Details
8/4/2016Q216$0.20$0.25$52.44 million$54.57 millionViewN/AView Earnings Details
5/9/2016Q116$0.12$0.11$41.75 million$43.00 millionViewN/AView Earnings Details
3/14/2016Q415$0.07$0.19$29.10 million$40.40 millionViewN/AView Earnings Details
11/10/2015Q315$0.13$0.13$36.99 million$40.80 millionViewListenView Earnings Details
8/11/2015Q215$0.15$0.17$36.88 million$44.00 millionViewListenView Earnings Details
5/12/2015Q1$0.07$0.08$29.98 million$33.70 millionViewListenView Earnings Details
4/27/2015Q115$0.03$0.06$19.80 million$29.10 millionViewN/AView Earnings Details
11/11/2014Q3 2014$0.06$0.11$28.00 million$29.40 millionViewN/AView Earnings Details
8/12/2014Q214$0.07$0.11$23.93 million$30.40 millionViewN/AView Earnings Details
5/13/2014Q114$0.04$0.05$20.70 million$23.60 millionViewN/AView Earnings Details
3/27/2014Q4 13$0.02$0.89$18.71 million$19.76 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Inogen (NASDAQ:INGN)
2017 EPS Consensus Estimate: $0.93
2018 EPS Consensus Estimate: $1.29
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.10$0.15$0.13
Q2 20172$0.26$0.32$0.29
Q3 20172$0.28$0.30$0.29
Q4 20172$0.20$0.25$0.23
Q1 20182$0.22$0.23$0.23
Q2 20182$0.29$0.57$0.43
Q3 20182$0.32$0.37$0.35
Q4 20182$0.28$0.29$0.29
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Inogen (NASDAQ:INGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Inogen (NASDAQ:INGN)
Insider Ownership Percentage: 5.31%
Insider Trades by Quarter for Inogen (NASDAQ:INGN)
Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)
Insider Trades by Quarter for Inogen (NASDAQ:INGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/18/2017Matt ScribnerEVPSell2,500$94.21$235,525.00View SEC Filing  
7/14/2017Raymond HuggenbergerDirectorSell14,000$92.96$1,301,440.00View SEC Filing  
6/16/2017Matt ScribnerEVPSell2,500$91.54$228,850.00View SEC Filing  
6/15/2017Raymond HuggenbergerDirectorSell15,300$90.88$1,390,464.00View SEC Filing  
6/2/2017Byron MyersEVPSell10,000$90.00$900,000.00View SEC Filing  
6/1/2017Scott WilkinsonInsiderSell23,437$88.06$2,063,862.22View SEC Filing  
5/30/2017Heath LukatchDirectorSell9,000$88.52$796,680.00View SEC Filing  
5/18/2017Ray Benjamin M AndersonDirectorSell4,445$81.05$360,267.25View SEC Filing  
5/10/2017Alison BauerleinEVPSell6,666$83.24$554,877.84View SEC Filing  
4/24/2017Byron MyersEVPSell10,000$80.00$800,000.00View SEC Filing  
4/17/2017Matt ScribnerEVPSell2,500$75.28$188,200.00View SEC Filing  
3/15/2017Matt ScribnerEVPSell2,500$73.85$184,625.00View SEC Filing  
2/28/2017Brenton TaylorEVPSell3,750$70.07$262,762.50View SEC Filing  
1/17/2017Matt ScribnerEVPSell2,500$63.91$159,775.00View SEC Filing  
1/17/2017Raymond HuggenbergerCEOSell5,680$63.96$363,292.80View SEC Filing  
1/10/2017Brenton TaylorEVPSell5,105$65.31$333,407.55View SEC Filing  
1/3/2017Brenton TaylorEVPSell31,823$65.69$2,090,452.87View SEC Filing  
12/15/2016Raymond HuggenbergerCEOSell8,000$65.59$524,720.00View SEC Filing  
12/14/2016Matt ScribnerEVPSell2,500$65.13$162,825.00View SEC Filing  
12/1/2016Scott WilkinsonInsiderSell26,706$61.64$1,646,157.84View SEC Filing  
11/14/2016Matt ScribnerEVPSell2,500$63.80$159,500.00View SEC Filing  
10/17/2016Raymond HuggenbergerCEOSell7,089$56.24$398,685.36View SEC Filing  
10/12/2016Matt ScribnerEVPSell4,551$59.45$270,556.95View SEC Filing  
9/19/2016Matt ScribnerEVPSell4,551$60.18$273,879.18View SEC Filing  
9/16/2016Byron MyersVPSell6,200$60.04$372,248.00View SEC Filing  
9/9/2016Byron MyersVPSell3,800$60.07$228,266.00View SEC Filing  
8/18/2016Matt ScribnerEVPSell2,320$56.39$130,824.80View SEC Filing  
8/15/2016Raymond HuggenbergerCEOSell20,747$57.48$1,192,537.56View SEC Filing  
8/9/2016Byron MyersVPSell13,000$55.00$715,000.00View SEC Filing  
7/18/2016Matt ScribnerEVPSell4,102$50.46$206,986.92View SEC Filing  
7/18/2016Raymond HuggenbergerCEOSell20,747$50.41$1,045,856.27View SEC Filing  
6/16/2016Matt ScribnerEVPSell4,102$47.66$195,501.32View SEC Filing  
6/16/2016Raymond HuggenbergerCEOSell20,747$47.86$992,951.42View SEC Filing  
5/16/2016Matt ScribnerEVPSell4,102$43.82$179,749.64View SEC Filing  
5/16/2016Raymond HuggenbergerCEOSell20,746$44.18$916,558.28View SEC Filing  
4/15/2016Matt ScribnerEVPSell4,102$48.62$199,439.24View SEC Filing  
4/15/2016Raymond HuggenbergerCEOSell29,635$48.59$1,439,964.65View SEC Filing  
4/13/2016Brenton TaylorEVPSell6,500$48.00$312,000.00View SEC Filing  
4/6/2016Alison BauerleinCFOSell9,278$46.18$428,458.04View SEC Filing  
3/31/2016Alison BauerleinCFOSell4,360$44.33$193,278.80View SEC Filing  
2/16/2016Matt ScribnerEVPSell4,102$30.26$124,126.52View SEC Filing  
1/14/2016Matt ScribnerEVPSell4,102$34.73$142,462.46View SEC Filing  
12/14/2015Matt ScribnerEVPSell4,102$40.40$165,720.80View SEC Filing  
11/12/2015Matt ScribnerEVPSell4,102$44.52$182,621.04View SEC Filing  
10/26/2015Brenton TaylorEVPSell5,000$41.38$206,900.00View SEC Filing  
10/21/2015Raymond HuggenbergerCEOSell57,418$43.06$2,472,419.08View SEC Filing  
10/12/2015Matt ScribnerEVPSell4,102$44.06$180,734.12View SEC Filing  
10/1/2015Alison BauerleinCFOSell10,185$47.94$488,268.90View SEC Filing  
9/25/2015Brenton TaylorEVPSell3,333$53.48$178,248.84View SEC Filing  
9/16/2015Byron MyersVPSell1,700$55.00$93,500.00View SEC Filing  
9/15/2015Raymond HuggenbergerCEOSell57,416$53.58$3,076,349.28View SEC Filing  
9/14/2015Byron MyersVPSell7,950$55.23$439,078.50View SEC Filing  
9/10/2015Matt ScribnerEVPSell4,102$53.30$218,636.60View SEC Filing  
9/1/2015Alison BauerleinCFOSell6,500$48.21$313,365.00View SEC Filing  
8/26/2015Scott WilkinsonEVPSell6,666$45.42$302,769.72View SEC Filing  
8/25/2015Brenton TaylorEVPSell3,333$46.84$156,117.72View SEC Filing  
8/25/2015Ray Benjamin M. AndersonDirectorSell5,658$46.36$262,304.88View SEC Filing  
5/28/2015Timothy PetersenDirectorSell337,081$37.44$12,620,312.64View SEC Filing  
5/26/2015Timothy PetersenDirectorSell54,258$37.05$2,010,258.90View SEC Filing  
5/22/2015Timothy PetersenDirectorSell86,889$37.09$3,222,713.01View SEC Filing  
5/21/2015Timothy PetersenDirectorSell134,300$37.81$5,077,883.00View SEC Filing  
5/19/2015Timothy PetersenDirectorSell115,700$37.25$4,309,825.00View SEC Filing  
5/18/2015Timothy PetersenDirectorSell58,987$37.35$2,203,164.45View SEC Filing  
3/5/2015Matt ScribnerEVPSell4,102$33.69$138,196.38View SEC Filing  
2/25/2015Brenton TaylorEVPSell15,687$33.87$531,318.69View SEC Filing  
2/23/2015Alison BauerleinCFOSell15,687$33.10$519,239.70View SEC Filing  
2/19/2015Raymond HuggenbergerCEOSell25,722$33.95$873,261.90View SEC Filing  
2/13/2015Scott WilkinsonEVPSell18,333$32.87$602,605.71View SEC Filing  
2/5/2015Matt ScribnerEVPSell4,102$30.66$125,767.32View SEC Filing  
2/3/2015Timothy PetersenDirectorSell17,000$30.25$514,250.00View SEC Filing  
2/2/2015Timothy PetersenDirectorSell99,000$30.88$3,057,120.00View SEC Filing  
1/29/2015Timothy PetersenDirectorSell601,000$31.95$19,201,950.00View SEC Filing  
1/26/2015Brenton TaylorEVPSell15,687$31.53$494,611.11View SEC Filing  
1/23/2015Alison BauerleinCFOSell15,687$31.53$494,611.11View SEC Filing  
1/20/2015Raymond HuggenbergerCEOSell25,722$31.63$813,586.86View SEC Filing  
1/5/2015Matt ScribnerEVPSell4,102$31.14$127,736.28View SEC Filing  
1/5/2015Versant Ventures Ii LlcMajor ShareholderSell7,946$30.98$246,167.08View SEC Filing  
12/30/2014Scott WilkinsonEVPSell962$30.50$29,341.00View SEC Filing  
12/29/2014Scott WilkinsonEVPSell15,735$30.52$480,232.20View SEC Filing  
12/24/2014Byron MyersVPSell7,514$30.07$225,945.98View SEC Filing  
12/23/2014Alison BauerleinCFOSell15,687$29.85$468,256.95View SEC Filing  
12/23/2014Byron MyersVPSell3,018$30.04$90,660.72View SEC Filing  
12/23/2014Versant Ventures Ii LlcMajor ShareholderSell9,785$29.74$291,005.90View SEC Filing  
12/22/2014Byron MyersVPSell11,801$30.06$354,738.06View SEC Filing  
12/22/2014Scott WilkinsonEVPSell1,033$30.31$31,310.23View SEC Filing  
12/19/2014Raymond HuggenbergerCEOSell25,722$28.98$745,423.56View SEC Filing  
12/11/2014Scott WilkinsonEVPSell14,700$25.25$371,175.00View SEC Filing  
12/3/2014Matt ScribnerEVPSell4,102$24.09$98,817.18View SEC Filing  
11/25/2014Brenton TaylorEVPSell15,687$24.71$387,625.77View SEC Filing  
11/21/2014Alison BauerleinCFOSell15,687$24.49$384,174.63View SEC Filing  
11/19/2014Raymond HuggenbergerCEOSell25,722$24.25$623,758.50View SEC Filing  
11/19/2014Versant Ventures Ii LlcMajor ShareholderSell28,225$24.77$699,133.25View SEC Filing  
11/18/2014Scott WilkinsonEVPSell2,233$25.21$56,293.93View SEC Filing  
11/18/2014Versant Ventures Ii LlcMajor ShareholderSell11,848$24.83$294,185.84View SEC Filing  
11/17/2014Versant Ventures Ii LlcMajor ShareholderSell5,343$24.89$132,987.27View SEC Filing  
11/14/2014Heather D RiderDirectorBuy3,000$25.00$75,000.00View SEC Filing  
11/14/2014Scott WilkinsonEVPSell1,100$25.15$27,665.00View SEC Filing  
11/14/2014Versant Ventures Ii LlcMajor ShareholderSell9,433$25.13$237,051.29View SEC Filing  
11/10/2014Versant Ventures Ii LlcMajor ShareholderSell2,992$24.42$73,064.64View SEC Filing  
11/7/2014Versant Ventures Ii LlcMajor ShareholderSell7,388$24.30$179,528.40View SEC Filing  
11/4/2014A/S NovoMajor ShareholderSell2,000,000$21.50$43,000,000.00View SEC Filing  
11/4/2014Raymond HuggenbergerCEOSell165,891$20.21$3,352,657.11View SEC Filing  
11/4/2014Timothy PetersenDirectorSell250,000$21.50$5,375,000.00View SEC Filing  
11/3/2014Matt ScribnerEVPSell4,102$24.08$98,776.16View SEC Filing  
10/29/2014Scott WilkinsonEVPSell18,333$22.41$410,842.53View SEC Filing  
10/27/2014Brenton TaylorEVPSell15,687$21.67$339,937.29View SEC Filing  
10/24/2014Versant Ventures Ii LlcMajor ShareholderSell4,647$20.76$96,471.72View SEC Filing  
10/23/2014Alison BauerleinCFOSell15,687$20.50$321,583.50View SEC Filing  
10/9/2014Versant Ventures Ii LlcMajor ShareholderSell1,900$20.83$39,577.00View SEC Filing  
10/8/2014Versant Ventures Ii LlcMajor ShareholderSell6,907$21.03$145,254.21View SEC Filing  
10/7/2014Timothy PetersenDirectorSell31,600$21.55$680,980.00View SEC Filing  
10/6/2014Timothy PetersenDirectorSell17,475$21.56$376,761.00View SEC Filing  
10/3/2014Timothy PetersenDirectorSell31,658$21.52$681,280.16View SEC Filing  
10/3/2014Ventures Lp Arboretum IIMajor ShareholderSell98,400$20.97$2,063,448.00View SEC Filing  
10/2/2014Timothy PetersenDirectorSell24,597$20.91$514,323.27View SEC Filing  
10/1/2014Matt ScribnerEVPSell8,204$20.25$166,131.00View SEC Filing  
10/1/2014Timothy PetersenDirectorSell42,145$20.61$868,608.45View SEC Filing  
9/30/2014Timothy PetersenDirectorSell84,500$20.23$1,709,435.00View SEC Filing  
9/24/2014Ventures Lp Arboretum IIMajor ShareholderSell83,500$20.34$1,698,390.00View SEC Filing  
9/23/2014Alison BauerleinCFOSell15,687$20.01$313,896.87View SEC Filing  
9/22/2014Raymond HuggenbergerCEOSell25,722$20.25$520,870.50View SEC Filing  
9/22/2014Timothy PetersenDirectorSell46,865$21.05$986,508.25View SEC Filing  
9/17/2014Timothy PetersenDirectorSell39,135$21.72$850,012.20View SEC Filing  
9/17/2014Ventures Lp Arboretum IIMajor ShareholderSell55,135$21.61$1,191,467.35View SEC Filing  
9/16/2014Timothy PetersenDirectorSell6,500$21.16$137,540.00View SEC Filing  
9/15/2014Byron MyersVPSell22,333$21.33$476,362.89View SEC Filing  
9/15/2014Scott WilkinsonEVPSell18,333$21.42$392,692.86View SEC Filing  
9/15/2014Timothy PetersenDirectorSell9,500$21.45$203,775.00View SEC Filing  
9/9/2014Versant Ventures Ii LlcMajor ShareholderSell7,388$23.25$171,771.00View SEC Filing  
3/7/2014Charles E LarsenDirectorSell26,201$14.88$389,870.88View SEC Filing  
2/20/2014A/S NovoInsiderSell617,000$14.88$9,180,960.00View SEC Filing  
2/20/2014Loren L McfarlandDirectorBuy3,125$16.00$50,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Inogen (NASDAQ:INGN)
Latest Headlines for Inogen (NASDAQ:INGN)
Source:
DateHeadline
americanbankingnews.com logoInogen, Inc (NASDAQ:INGN) Expected to Post Quarterly Sales of $60.29 Million
www.americanbankingnews.com - July 22 at 10:57 AM
americanbankingnews.com logoInsider Selling: Inogen, Inc (INGN) EVP Sells 2,500 Shares of Stock
www.americanbankingnews.com - July 20 at 4:34 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Inogen, Inc (INGN) to Announce $0.28 Earnings Per Share
www.americanbankingnews.com - July 20 at 8:44 AM
finance.yahoo.com logo3 Stocks That Look Today Like Activision Blizzard Did in 2014
finance.yahoo.com - July 19 at 7:04 AM
americanbankingnews.com logoRaymond Huggenberger Sells 14,000 Shares of Inogen, Inc (INGN) Stock
www.americanbankingnews.com - July 18 at 10:28 PM
nasdaq.com logoThe INGN Paradox: Analysts Bullish But Forecast -1.35% Fall
www.nasdaq.com - July 18 at 1:34 AM
americanbankingnews.com logoInogen, Inc (NASDAQ:INGN) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - July 11 at 1:46 PM
americanbankingnews.com logoHead-To-Head Contrast: Inogen (NASDAQ:INGN) versus Bio-Rad Laboratories (BIO)
www.americanbankingnews.com - July 11 at 12:22 PM
americanbankingnews.com logoInogen, Inc (INGN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 11 at 8:04 AM
finance.yahoo.com logoNevro (NVRO) Surges: Stock Moves 11.4% Higher
finance.yahoo.com - July 7 at 6:28 AM
zacks.com logoOmnicell (OMCL) Rides on Acquisitions Amid Tough Competition
www.zacks.com - July 5 at 8:21 AM
americanbankingnews.com logoInogen, Inc (INGN) Expected to Post Quarterly Sales of $59.17 Million
www.americanbankingnews.com - June 28 at 12:52 PM
americanbankingnews.com logoJ P Morgan Chase & Co Increases Inogen, Inc (INGN) Price Target to $102.00
www.americanbankingnews.com - June 26 at 10:31 AM
americanbankingnews.com logoZacks: Analysts Anticipate Inogen, Inc (INGN) Will Post Earnings of $0.28 Per Share
www.americanbankingnews.com - June 26 at 7:44 AM
finance.yahoo.com logoGenomic Health Cancer Tests Strong, Operating Expenses a Woe
finance.yahoo.com - June 21 at 3:37 PM
finance.yahoo.com logoMedtronic CRT Devices Improve Therapy Delivery, Cut Costs
finance.yahoo.com - June 21 at 3:37 PM
finance.yahoo.com logoPAREXEL Announces Acquisition by Pamplona Capital for $5B
finance.yahoo.com - June 21 at 3:37 PM
finance.yahoo.com logoPerkinElmer (PKI) to Acquire German Firm EUROIMMUN for $1.3B
finance.yahoo.com - June 21 at 3:37 PM
americanbankingnews.com logoInogen, Inc (INGN) EVP Matt Scribner Sells 2,500 Shares
www.americanbankingnews.com - June 19 at 7:34 PM
americanbankingnews.com logoInsider Selling: Inogen, Inc (INGN) Director Sells 15,300 Shares of Stock
www.americanbankingnews.com - June 19 at 7:20 PM
finance.yahoo.com logoETFs with exposure to Inogen, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 4:55 PM
nasdaq.com logoInogen (INGN) Scores a Strong Buy Right Now: Here's How
www.nasdaq.com - June 19 at 12:21 PM
finance.yahoo.com logoInogen, Inc. :INGN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 17 at 12:04 AM
finance.yahoo.com logoWhy Does Intuitive Surgical Score as a Strong Buy Right Now
finance.yahoo.com - June 16 at 6:49 PM
americanbankingnews.com logoInogen, Inc (INGN) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - June 16 at 10:06 AM
finance.yahoo.com logoCivitas Solutions (CIVI) Extends ADH Platform to New Jersey
finance.yahoo.com - June 14 at 11:22 AM
finance.yahoo.com logoLuminex's (LMNX) VERIGENE Panels Receive Approval in Japan
finance.yahoo.com - June 13 at 5:41 PM
nasdaq.com logoInogen (INGN) Up 8% Since Earnings Report: Can It Continue?
www.nasdaq.com - June 13 at 10:55 AM
finance.yahoo.com logoMead Johnson-Reckitt Move to Merge, Deal Closes on Jun 15
finance.yahoo.com - June 13 at 10:55 AM
americanbankingnews.com logoNeedham & Company LLC Raises Inogen Inc (INGN) Price Target to $108.00
www.americanbankingnews.com - June 9 at 3:22 PM
finance.yahoo.com logoMedtronic Launches MiniMed 670G to Better Manage Diabetes
finance.yahoo.com - June 9 at 3:21 PM
americanbankingnews.com logoInogen Inc (INGN) Price Target Raised to $108.00
www.americanbankingnews.com - June 8 at 3:28 PM
americanbankingnews.com logoNeedham & Company LLC Boosts Inogen Inc (INGN) Price Target to $108.00
www.americanbankingnews.com - June 8 at 10:58 AM
americanbankingnews.com logoInogen Inc (INGN) Price Target Increased to $108.00 by Analysts at Needham & Company LLC
www.americanbankingnews.com - June 8 at 9:38 AM
americanbankingnews.com logoInogen Inc (INGN) PT Raised to $108.00 at Needham & Company LLC
www.americanbankingnews.com - June 8 at 9:02 AM
americanbankingnews.com logoInogen Inc (INGN) Price Target Raised to $108.00 at Needham & Company LLC
www.americanbankingnews.com - June 8 at 8:01 AM
finance.yahoo.com logoHealthEquity (HQY) Q1 Earnings and Revenues Beat Estimates
finance.yahoo.com - June 7 at 10:07 AM
finance.yahoo.com logoBoston Scientific Wins CE Mark for Vercise Gevia DBS System
finance.yahoo.com - June 7 at 10:07 AM
finance.yahoo.com logoMedtronic SureTune3 Obtains Health Canada License for DBS
finance.yahoo.com - June 7 at 10:07 AM
americanbankingnews.com logoHead-To-Head Analysis: West Pharmaceutical Services (WST) versus Inogen (INGN)
www.americanbankingnews.com - June 5 at 8:47 PM
americanbankingnews.com logoScott Wilkinson Sells 23,437 Shares of Inogen Inc (INGN) Stock
www.americanbankingnews.com - June 5 at 4:18 PM
americanbankingnews.com logoInogen Inc (INGN) EVP Sells $900,000.00 in Stock
www.americanbankingnews.com - June 5 at 4:18 PM
finance.yahoo.com logoInogen Secures Additional Facility to Support Direct-to-Consumer Sales Growth
finance.yahoo.com - June 2 at 7:19 PM
americanbankingnews.com logoInogen Inc (INGN) Expected to Announce Quarterly Sales of $59.17 Million
www.americanbankingnews.com - June 2 at 4:06 PM
finance.yahoo.com logoInogen Broadens Market Access for Innovative Portable Oxygen Concentrator
finance.yahoo.com - June 1 at 6:45 PM
finance.yahoo.com logoMedtronic Starts PRODIGY Study on Respiratory Compromise
finance.yahoo.com - June 1 at 6:45 PM
americanbankingnews.com logoInsider Selling: Inogen Inc (INGN) Director Sells 9,000 Shares of Stock
www.americanbankingnews.com - May 31 at 7:24 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Inogen Inc (INGN) Will Post Earnings of $0.28 Per Share
www.americanbankingnews.com - May 31 at 10:02 AM
finance.yahoo.com logoInogen Announces Participation in 37th Annual William Blair Growth Stock Conference
finance.yahoo.com - May 30 at 5:43 PM
finance.yahoo.com logoMyriad Genetics Gets Extended Coverage for Prolaris Test
finance.yahoo.com - May 29 at 9:32 AM

Social

Chart

Inogen (INGN) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by MarketBeat.com Staff